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Objective: To evaluate efﬁ  cacy and safety of intravitreal injections of bevacizumab in the 
treatment of macular edema secondary to retinal vein occlusion (RVO).
Methods: Prospective study, noncomparative, interventional case series. Twelve consecutive 
patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were 
treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic 
evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measure-
ment using ETDRS charts, and imaging with ocular coherence tomography evaluating changes 
in foveal thickness (FT) and macular volume (MV).
Results: The median age was 66 years (± 4.16), and the median duration of symptoms was 
4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior 
branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline 
to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, 
and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean 
FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean 
MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up.
Keywords: Bevacizumab, retinal vein occlusion, intravitreal injection, vascular endothelial 
growth factor
Introduction
Retinal vein occlusion (RVO) is the second most common retinal vascular disease, 
after diabetic retinopathy. Visual loss may result from ischemic damage and/or macular 
edema. Early treatment may be required to improve vision because longstanding 
macular edema results in irreversible photoreceptor damage (CRVO 1995). Intravit-
real triamcinolone is a treatment option that has demonstrated promising short-term 
results for the management of macular edema associated with RVO (Mohammed et al 
2007). A multicenter, randomized and controlled clinical trial (Standard Care Versus 
Corticosteroid for Retina Vein Occlusion Study) is currently underway.
Retinal vein occlusion is associated with varying amounts of retinal ischaemia and, 
consequently, increased concentrations of vascular endothelial growth factor (VEGF) 
(Hayreh 1983). Early case reports on bevacizumab showed an increase in visual acuity 
(VA) and a decrease in macular edema secondary to exudative age-related macular 
degeneration (AMD) and central retinal vein occlusion (CRVO) (Rosenfeld et al 
2005a). A nonrandomized study of intravitreal bevacizumab in patients with CRVO 
resulted in reduced macular swelling and increased VA (Iturralde et al 2006). However, 
because a physiological level of vascular endothelial growth factor may be necessary 
to maintain the homeostasis of the retina, care might be required to avoid the possible 
negative consequences of a complete blockade of VEGF.Clinical Ophthalmology 2008:2(4) 788
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These reports, along with results from preclinical and 
human studies that suggest a possible role of VEGF in RVO 
and the absence of a proven therapy, prompted us to inves-
tigate the effects of intravitreal bevacizumab injection in 
patients with macular edema associated with RVO.
Methods
Study design
This was a prospective, consecutive, noncomparative study 
that adhered to the Declaration of Helsinki and which was 
approved by our institutional review board. An intravitreal 
off-label bevacizumab injection was recommended. The 
Spanish Ministry of Health and Consumer Affairs approved 
compassionate use. Patients were fully informed verbally 
about the experimental nature of the treatment and they 
signed an informed consent form.
Cases were recruited from the Hospital Universitari de 
Bellvitge (Barcelona, Spain) from January–March 2007. 
Inclusion criteria were: 1) patients aged 50 or older 2) macular 
edema secondary to nonischemic RVO and 3) VA between 
20/400 and 20/50 (Snellen equivalent). Exclusion criteria 
were: 1) history of retinal surgery or photocoagulation; 2) any 
history of a thromboembolic event; 3) bleeding disorders; 
and 4) use of anticoagulative medication other than aspirin. 
No patient refused treatment.
A comprehensive ophthalmic evaluation was per-
formed; it included a medical history review, best corrected 
visual acuity testing (using ETDRS charts), slit-lamp 
biomicroscopy, dilated funduscopic examination using a 
78-diopters lens and time domain ocular computed tomog-
raphy (OCT) (Carl Zeiss Meditec, Dublin, CA, USA) that 
consisted of an acquisition protocol “Radial lines” (6 linear, 
6 mm scans oriented at intervals of 30° and centered on the 
foveal region). Macular maps were obtained using the “retinal 
thickness/volume” analysis protocol, and values for central 
foveal thickness (FT) and total macular volume (MV) were 
recorded. Follow-up examinations were scheduled at weeks 
1, 4, 12, and 24 post-injection, or on demand, if a decrease in 
VA was noted by the patient. These follow-up examinations 
used exactly the same procedures as those used in the base-
line visit. The incidence of adverse events were monitored 
throughout the study. The effects of treatment, both on VA 
and on anatomical changes in the macula shown by OCT, 
were evaluated. There was no loss of follow-up.
Treatment procedure
Patients received an intravitreal dosage of bevacizumab of 
1.25 mg (0.05 mL) at baseline and once every four weeks if 
OCT indicated macular swelling (quantitatively characterized 
by a macular thickness larger than 250 microns in any of the 
six radial scans). All treatments were performed in the ofﬁ  ce 
using topical anaesthesia (tetracaine+oxibuprocaine) under 
sterile conditions. Bevacizumab was injected (using a 30-G 
needle) through the inferotemporal pars plana, 3.5 mm (pseu-
dophakic) or 4 mm (phakic) posterior to the limbus. A drop of 
oﬂ  oxacine was applied to the affected eye immediately after 
the procedure and again every 6 hours for 4 days.
Statistical data analysis
All data were collected in an Microsoft Excel 2000 
spreadsheet (Microsoft Corporation, Spain). For statistical 
analysis, the Wllcoxon test was performed. VA measurements 
were converted to logMAR equivalents to perform analysis. 
p  0.05 was considered signiﬁ  cant.
Results
Twelve patients (seven women and ﬁ  ve men) were included. 
The median age was 66 years and the median duration of 
symptoms prior to treatment was 4 months. Vein occlusion 
was located at the inferior branch in six patients and at the 
superior branch in the remaining six patients. There was a 
history of hypertension in four patients. All patients com-
pleted the 24-week follow-up examination; their baseline 
characteristics are summarized in Table 1.
Best corrected visual acuity (BCVA) data obtained 
over the course of the study are summarized in Table 2. 
Evaluation of BCVA revealed signiﬁ  cant improvement at 
all times compared with baseline. Mean VA improved from 
1.32 ± 0.24 (logMAR values) at baseline, to 0.8 ± 0.15 
(p = 0.0003) at the 6-month follow-up. The macular edema 
responded promptly, and a reduction in the submacular ﬂ  uid 
was observed at the seventh day. At baseline, the mean FT 
was 615.50 ± 116.29 microns; it declined to 420 ± 72.53 
microns (p = 0.001). The mean MV improved from 19.81 ± 
2.31 mm3 to 9.23 ± 1.38 mm3 (p = 0.0001) at the 6-month 
follow-up. Mean changes in parameters recorded by OCT 
on weeks 1, 4, 12, and 24 post-injection are summarized 
in Table 3. Overall, four patients were retreated: 2 patients 
received two consecutive injections of intravitreal bevaci-
zumab, and two patients received three injections. No ocular 
or systemic adverse events were observed.
Discussion
This study demonstrates the early and clinically relevant 
beneﬁ  ts of bevacizumab injection for macular edema due to 
RVO. In this prospective case series, we found that intravitreal Clinical Ophthalmology 2008:2(4) 789
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injections of bevacizumab led both to a signiﬁ  cant reduction 
of FT, as well as to an improvement of visual acuity in patients 
with RVO. A beneﬁ  cial effect of intravitreal bevacizumab 
was observerd as early as the ﬁ  rst week and over a 6-month 
follow-up period.
Our study supports the preliminary results of several 
recently published papers. The most detailed data on the 
natural history of CRVO were provided by the Central Vein 
Occlusion Study Group (CRVO 1995). Clinical outcomes of 
every new treatment option for CRVO must match with these 
data. In the natural course of CRVO, only 19% of patients 
with initial visual acuity of less than 20/200 had a chance of 
visual acuity of better than 20/200. Patients presenting with 
initial visual acuity between 20/200 and 20/50 had improve-
ment to better than 20/50 in 19% of cases; in 44% of cases 
acuity stayed between 20/200 and 20/50. The visual acuity of 
only 37% of patients became worse than 20/200. Compared 
with these data, patients treated with intravitreal injections of 
bevacizumab showed much greater improvement. Priglinger 
and colleagues (2007) reported improvement in visual acuity 
from 20/250 at baseline to 20/80 at the 6-month follow-up 
(p  0.001) in a group of 46 CRVO patients. Mean central 
retinal thickness decreased from 535 ± 48 microns at baseline 
to 323 ± 116 microns at the 6-month follow-up (Priglinger 
et al 2007). In a series of 30 CRVO patients followed for 
6 months, Jason and colleagues (2007) reported improvement 
in VA from 20/394 at baseline to 20/313 at the 3-month 
follow-up, (p  0.05) and no signiﬁ  cant changes after the 
fourth month. This indicates that bevacizumab represents an 
effective treatment option for CRVO and that the drug may 
improve the long-term prognosis of CRVO.
The intravitreal use of bevacizumab may provide anatomi-
cal and functional amelioration of the macula in patients with 
macular edema due to RVO. The electrical responses in the 
fovea and parafovea of the multifocal electroretinography 
recording depict a signiﬁ  cant improvement at 1 and 3 months 
after the injection (Moschos and Moschos 2008).
Table 1 Baseline characteristics
Case,  age, sex Affected ye, localization Duration (months) logMAR BCVA OCT FT (microns) OCT MV (mm3)
1, 64, F OD, inferior 2.5 0.63 664 12.91
2, 63, F OD, inferior 5 1.7 545 22.17
3, 75, M OD, superior 6 1.05 410 16.65
4, 57, M OD, superior 3 1.63 667 21.23
5, 67, F OD, superior 2.5 1.96 601 20.82
6, 66, F OS, inferior 2 0.62 763 11.9
7, 61 F OD, superior 3 1.6 495 21.16
8, 75, F OD, superior 4 1.04 630 15.64
9, 77, M OS, superior 4 1.62 239 20.22
10, 66, M OS, inferior 7 1.34 885 12.97
11, 59, M OS, inferior 6 1.3 498 11.2
12, 79, F OS, inferior 7 0.96 998 19.81
Median: 66
SD: 7,26
Conﬁ  dence 
intervals (CI): 4.16
Median: 4
SD: 1.81
CI: 1.02
Median: 1.32
SD: 0.43
CI: 0.24
Median: 615.50
SD: 205.547
CI: 116.29
Median: 19.81
SD: 4.10
CI: 2.31
Abbreviations: F, female; M, male; SD, standard deviation; OD, right eye; OS, left eye; BCVA, best corrected visual activity; FT, foveal thickness; MV, macular volume.
Table 2 logMAR BCVA (baseline and 1, 4 12, and 24 weeks 
post-injection)
logMAR 
BCVA 
baseline
logMAR 
BCVA, 
week 1
logMAR 
BCVA 
week 4
logMAR 
BCVA 
week 12
logMAR 
BCVA 
week 24
0.63 0.35 0.17 0.23 0.43
1.7 1.3 0.75 0.77 0.77
1.05 1.01 1.03 1 0.89
1.63 1.47 1.2 1.35 1.17
1.96 0.4 0.43 0.61 0.53
0.62 0.36 0.17 0.23 0.42
1.6 1.2 0.75 0.78 0.76
1.04 1.02 1.02 1 0.86
1.62 1.48 1.3 1.36 1.19
1.34 1 0.78 0.86 0.83
1.3 1.28 1.24 1.28 1.25
0.96 0.5 0.42 0.62 0.56
Note: p (baseline-week 24) = 0.0003
Abbreviation: BCVA, best corrected visual acuity.Clinical Ophthalmology 2008:2(4) 790
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Intravitreal injection of triamcinolone acetonide (TA) is 
another treatment option aimed to reduce macular edema 
after RVO. Several recent studies report favorable effects 
of intravitreal injection (4–20 mg) of TA on the course of 
RVO (Gregory et al 2006). The extent and duration of the 
effect of intravitreal injection of TA depends on the dose 
used and the presence of retinal ischemia (Jonas et al 2005). 
Repeated intravitreal injections of TA are possible; however, 
after repeated treatments, the effect on reduction of retinal 
thickness and increase in visual acuity are reduced (Boyd 
et al 2002; Kupperman et al 2007). Furthermore, although 
apparently improving the clinical outcome of RVO, repeated 
intravitreal injections of TA are associated with many poten-
tial complications, such as elevated intraocular pressure 
and cataract formation, which may ultimately decrease the 
long-term prognosis of RVO (Goff et al 2006). In contrast to 
intravitreal injection of TA, several injections of bevacizumab 
appear to have no drug-related complications. However, 
complications related to repeated intravitreal injections 
(eg, endophthalmitis, retinal tear, and lens trauma) must be 
taken into account (Jaissle et al 2006). Fortunately, none of 
these complications occurred in the present case series; this 
may be due to the thorough prophylactic, antiseptic regimen 
applied in our institution to minimize the likelihood of bacte-
rial contamination.
The use of anti-VEGF agents in retinal disease has 
become increasingly common since the approval (in 2004 
and 2006, respectively) of pegaptanib and ranibizumab for 
age-related maculopathy. These agents are currently being 
studied for their efﬁ  cacy against macular edema due to RVO. 
The anti-VEGF agent most studied in regard to RVO is 
bevacizumab. Off-label intravitreal injection of bevacizumab 
was ﬁ  rst reported in 2005 to represent a potential therapy for 
macular edema secondary to CRVO (Rosenfeld et al 2005b). 
Since then, several additional publications have reported 
favorable short-term results for reduction of macular edema 
and improvement of vision in patients with RVO (Spandau 
et 2006; Pau et al 2007).
Our results suggest a possible short-term beneﬁ  t for 
macular architecture and VA; however, it is also clear that 
such beneﬁ  ts are transient. Continuous VEGF suppression 
may be required to sustain beneﬁ  cial effects observed in the 
short term and the risks associated with multiple intravit-
real injections need to be considered. Our data suggest that 
patients may require several injections to maintain efﬁ  cacy. 
Three to four months after the most recent injection, wors-
ening VA was detected in about half of the cases. The data 
in this study suggest that a single injection of intravitreal 
bevacizumab has a limited beneﬁ  cial effect for approximately 
two months in most patients.
Although VEGF and its receptors represent potential 
targets for pharmacologic intervention, several important 
questions remain. Does VEGF play a role in the formation 
of vascular shunts across ischemic areas? Does continuous 
blockage of VEGF have a negative effect over the long term? 
Furthermore, recurrent macular edema may occur in patients 
Table 3 FT (microns) and MV (mm3) (baseline and 1, 4, 12. and 
24 week post-injection)
Case 1 Baseline Week 1 Week 4 Week 12 Week 24
FT 664 220 166 167 189
MV 12.91 8.48 7.87 8.38 8.34
Case 2
FT 545 440 165 481 654
MV 22.17 6.96 6.64 9.33 8.35
Case 3
FT 410 166 496 509 578
MV 16.65 12.17 13.2 13.95 12.95
Case 4
FT 667 565 459 500 475
MV 21.23 17.32 15.16 15.69 14.63
Case 5
FT 601 436 175 501 420
MV 20.82 6.66 6.83 9.2 9.5
Case 6
FT 763 400 170 456 432
MV 11.9 7.47 6.86 7.37 10.56
Case 7
FT 495 175 195 225 235
MV 21.16 5.95 5.63 8.32 7.35
Case 8
FT 630 220 460 335 342
MV 15.64 11.16 12.1 12.94 10.55
Case 9
FT 239 442 336 402 389
MV 20.22 16.31 12.1 14.68 12.48
Case 10
FT 885 296 450 425 420
MV 12.97 6.25 10.91 10.55 8.95
Case 11
FT 498 345 450 356 352
MV 11.2 10.72 5.82 10.97 7.55
Case 12
FT 998 425 182 522 425
MV 19.81 5.55 5.85 8.1 6.98
Notes: p (baseline- week 24): FT = 0.001 MV = 0.0001
Abbreviations: FT, foveal thickness; MV, and macular volume.Clinical Ophthalmology 2008:2(4) 791
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with RVO following treatment with bevacizumab; in some 
cases, the recurrent macular edema may be more severe than 
the pre-treatment macular edema (a phenomenon known as 
“rebound” macular edema) (Matsumoto et al 2007).
The changes observed throughout the present study may 
provide important clues about drug effects and duration. 
Favorable macular changes, documented by OCT, were 
evident as soon as day 7 post-injection. While these improve-
ments were maintained at post-injection week 4, there was a 
clear tendency for macular edema to recur around week 12; 
this suggests, therefore, that reinjections might be considered 
at some point during this period when a 1.25 mg dose regimen 
is used in setting of ischemic or nonischemic RVO.
The present study does have some limitations that must 
be recognized: there was no control group; we included 
only 12 patients and there was only a limited follow-up. 
However, the promising results reported here indicate that 
further studies of intravitreal bevacizumab injection for the 
management of ischemic or nonischemic RVO are justiﬁ  ed. 
Future well-designed studies will help to establish the role of 
antiangiogenic therapy in the management of RVO.
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